- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04129294
Exploratory Study of NS-089/NCNP-02 in DMD
Exploratory Study of NS-089/NCNP-02 in Duchenne Muscular Dystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Tokyo
-
Kodaira, Tokyo, Japan, 1878551
- National Center of Neurology and Psychiatry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has an out of frame deletion(s) that could be corrected by skipping exon 44 as confirmed by any of methodology at the time of visit 1. If not confirmed by any of methodology that evaluates the relative copy number of all exons (i.e. MLPA etc), must be confirmed through these techniques by the time of visit 3.
- DNA sequencing of exon 44 confirms that no DNA polymorphisms occur that could compromise duplex formation between NS-089/NCNP-02 and pre-mRNA.
- Male and >= 8 years and < 17 years of age at the time of obtaining informed consent and/or assent. Subjects aged >= 4 years and < 8 years can be enrolled according to the circumstances.
- Able to give informed consent in writing signed by parent(s) or legal guardian who is able to understand all of the study procedure requirements. If applicable, able to give informed assent in writing signed by the subject.
- Life expectancy of at least 1 year
- Able to ambulate. Non-ambulant subject can be enrolled according to the circumstances.
- Have intact muscles, which have adequate quality for biopsy. (No lacks or severe atrophy of biceps brachii or tibialis anterior muscle)
- QTc <450 msec (based on 12-lead ECGs), or <480 msec for subject with Bundle Branch Block.
- Glucocorticoid-naive patients, or patients who have used systemic glucocorticoids for at least 6 months prior to enrollment in this study with no dose changes for at least 3 months prior to enrollment.
Exclusion Criteria:
- Has participated in other pharmacological clinical trial that might recover dystrophin protein by the readthrough or the exon-skipping therapy, and/or upregulate the dystrophin-associated proteins such as utrophin.
- A forced vital capacity (FVC) < 50% of predicted.
- Continuous use of artificial respirator (except for use of NPPV while sleeping)
- A left ventricular ejection fraction (EF) < 40% or fractional shortening (FS) < 25% based on echocardiogram (ECHO).
- Surgery within the last 3 months prior to the first anticipated administration of study medication or planned for anytime between visit 1 of Part 1 and the last visit of Part 2.
- Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody test (HCV), or human immunodeficiency virus (HIV) test at screening.
- Current diagnosis of any immune deficiency or autoimmune disease.
- Current diagnosis of any active or uncontrolled infection, cardiomyopathy, or liver or renal disease.
- Use of any other investigational agents and/or experimental agents within 3 months prior to the first anticipated administration of study medication.
- History of any severe drug allergy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NS-089/NCNP-02
|
NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels. "[Part 1] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2. Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks [Part 2] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks." |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event and adverse drug reaction [Safety and Tolerability]
Time Frame: At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
adverse event and adverse drug reaction
|
At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expression of dystrophin protein
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Expression of dystrophin protein
|
At the end of the treatment period (24 weeks) of Part 2
|
NSAA
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
North Star Ambulatory Assessment
|
At the end of the treatment period (24 weeks) of Part 2
|
TTSTAND
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Time to Stand Test
|
At the end of the treatment period (24 weeks) of Part 2
|
TTRW
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Time to Run/Walk 10 Meters test
|
At the end of the treatment period (24 weeks) of Part 2
|
6MWT and 2MWT
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Six-Minute Walk Test (6MWT) and Two-Minute Walk Test (2MWT)
|
At the end of the treatment period (24 weeks) of Part 2
|
TUG
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Timed Up & Go (TUG) test
|
At the end of the treatment period (24 weeks) of Part 2
|
PUL
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Performance of Upper Limb test
|
At the end of the treatment period (24 weeks) of Part 2
|
Detection of exon 44-skipped mRNA of dystrophin in muscle tissue
Time Frame: At the end of the treatment period (24 weeks) of Part 2
|
Detection of exon 44-skipped mRNA of dystrophin in muscle tissue
|
At the end of the treatment period (24 weeks) of Part 2
|
NS-089/NCNP-02 concentration of the blood plasma
Time Frame: At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
NS-089/NCNP-02 concentration of the blood plasma
|
At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
Serum Creatine kinase concentration
Time Frame: At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
Serum Creatine kinase concentration
|
At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Hirofumi Komaki, MD, PhD, National Center of Neurology and Psychiatry, Japan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCNP/DMT02
- UMIN000038505 (Other Identifier: UMIN-CTR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on NS-089/NCNP-02
-
Nippon Shinyaku Co., Ltd.Active, not recruiting
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.RecruitingDuchenne Muscular DystrophyUnited States
-
NS Pharma, Inc.Cooperative International Neuromuscular Research Group; Nippon Shinyaku Co.... and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.CompletedDuchenne Muscular DystrophySpain, United States, Russian Federation, Italy, China, Turkey
-
National Center of Neurology and Psychiatry, JapanNippon Shinyaku Co., Ltd.Completed
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.Active, not recruitingDuchenne Muscular DystrophyKorea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
-
NS Pharma, Inc.Cooperative International Neuromuscular Research Group; Nippon Shinyaku Co.... and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada
-
NS Pharma, Inc.Approved for marketingMuscular Dystrophy, Duchenne | DMD
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.CompletedDuchenne Muscular DystrophyKorea, Republic of, Chile, Taiwan, China, United States, United Kingdom, Netherlands, Spain, Australia, Norway, Russian Federation, Greece, Italy, Turkey, Mexico, Canada, Hong Kong, New Zealand, Ukraine
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.Not yet recruiting